1.	Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 10-067, NCT01169649
2.	MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2010-02270, 2010-0247, N01CM00039, MDA-2010-0247, 8727, NCT01239342
3.	A Phase II Study of MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2013-00549, 10-402, NCT01283035
4.	AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2010-02186, 2010-0243, N01CM62202, N01CM00039, NCT01253447
5.	MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02974, OSU 10104, N01CM00070, 8735, NCT01425879
6.	Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01966, A091104, N01CM62206, U10CA031946, CDR0000733948, CALGB-A091104, NCT01604772
7.	A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5) Phase: Phase I Type: Treatment Status: Completed Age: 18 to 91 Sponsor: Pharmaceutical / Industry Protocol IDs: 2009_547, MK-2206-003, NCT00848718
8.	A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (2206-015) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2009_646, MK2206-015, NCT00963547
9.	A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM6) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2206-010, 2009_698, NCT01021748
10.	Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 and over Sponsor: Other Protocol IDs: 201001017M, NCT01147211
11.	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 1 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02612, ADVL1013, CDR0000687929, COG-ADVL1013, U01CA097452, NCT01231919
12.	MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02562, 2010-0245, CDR0000690723, U01CA062461, MDA-2010-0245, 8739, NCT01263145